Benzinga Pro offers a real-time newsfeed as headlines break on earnings releases, analyst ratings, rumors, the biggest movers, and many more actionable alerts.

Find Stocks Tailored to Your Trading Interests

benzingaproreview-1-1280x720

acf/call-to-action

<a href="https://share.hsforms.com/1kQ-soZmmTRqplsRXp5Zfpw1npzh">Claim Exclusive Offers</a>

Compare Investing Brokers (USE THIS ONE)

acf/widget-container

acf/compare-products

IBKR Stocks

Plus500 Yield

public.com

Robinhood

TradeZero

Compare Crypto Brokers Homepage

Gemini Crypto

Plus500 Crypto

Kraken

Binance NON US

Compare Brokers Table – Benzinga.com

Seres Therapeutics

Alkermes

Vaxcyte

BioNTech

Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc. - Common Stock

United Therapeutics

United Therapeutics Corporation - Common Stock

Erasca

Royalty Pharma

Royalty Pharma plc - Class A Ordinary Shares

Johnson & Johnson

Amylyx Pharma

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals

Revance Therapeutics

REVANCE THERAPEUTICS INC COM

Organon

Eli Lilly and Co

Eli Lilly

Schrodinger

Neurocrine Biosciences

Neurocrine Biosciences, Inc. - Common Stock

AbbVie

Nektar Therapeutics

Bristol-Myers Squibb

Bristol-Myers Squibb Company Common Stock

EQRx

Innoviva

Revolution Medicines

Revolution Medicines, Inc. - Common Stock

Prometheus Biosciences

Ventyx Biosciences

Kymera Therapeutics

Pfizer

Entrada Therapeutics

Entrada Therapeutics, Inc. - Common Stock

Exscientia

Tango Therapeutics

Arena Pharmaceuticals

Repare Therapeutics

Ardelyx

Aduro Biotech

Puma Biotechnology

Mirati Therapeutics

Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends.

Chris Shibutani's

Merck & Co. Inc. (NYSE: MRK)

On Tuesday,&nbsp;Merck&nbsp;&amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the&nbsp;consensus estimate of $15.49 billion. Excluding the impact of foreign exchange, <a target="_blank" href="https://www.benzinga.com/quote/MRK" rel="noreferrer noopener">sales increased 9%</a>.



Merck reported adjusted EPS of $1.72, up from $0.03 a year ago and beating the&nbsp;consensus of $1.62. Lower charges for business development transactions and operational strength&nbsp;<a target="_blank" href="https://www.benzinga.com/25/02/43461426/mercks-gardasil-vaccine-slowdown-in-china-bites-again-stock-falls-on-lower-than-expected-2025-outlook" rel="noreferrer noopener">primarily drove the increase</a>.



Merck expects fiscal year 2025 sales of $64.1 billion-$65.6 billion versus a consensus of $67.31 billion.



Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/43166965/senate-hearings-loom-as-robert-f-kennedy-faces-scrutiny-over-conflicts-of-interest-in-mercks-gardasil-vaccine-litigation" rel="noreferrer noopener">RJK Jr.'s Involvement In Merck Lawsuit Faces Scrutiny Ahead Of Senate Hearing</a>



The sales range reflects a decision to temporarily pause Gardasil/Gardasil 9 shipments into China beginning February 2025 through at least mid-year.



Goldman Sachs analyst writes that Merck delivered strong operational performance across the majority of the company's market-leading (Oncology), attractively emerging (PAH), and re-emerging competitive (Infectious disease) portfolios; however, weaker guidance was a source of disappointment.



Analyst Chris Shibutani writes that the magnitude of the downside move was overdone and maintains the Buy rating with a price forecast of $135, up <a target="_blank" href="https://www.benzinga.com/quote/MRK/analyst-ratings" rel="noreferrer noopener">from a prior $129</a>.



Across the commercial portfolio, the analyst remains bullish on Winrevair's potential.



Analyst Shibutani writes that the company is well-equipped to invest in business growth and prioritize capital allocation effectively. Their track record shows that they can successfully make strategic moves—both aggressive, like acquiring Acceleron and Prometheus, and cautious, like passing on Seagen due to valuation concerns.



BofA Securities writes Merck stock's valuation was too low for an above-average growth profile.



A BofA analyst notes that Merck has one of the strongest late-stage drug pipelines among its peers and remains a top-tier R&amp;D company. They still see more potential gains than risks at current levels and maintain a Buy rating. However, BofA writes the stock may take some time to stabilize in the short term.



The analyst lowered the price target from $118 to $112.



Price Action: MRK stock is down 0.79% at $90.02 at the last check on Wednesday.



Read Next:



<ul>
<li><a href="https://www.benzinga.com/25/02/43495757/t-mobile-raises-294-billion-to-fund-stock-buybacks-dividends-and-debt-refinancing" target="_blank" rel="noreferrer noopener">T-Mobile Raises $2.94 Billion To Fund Stock Buybacks, Dividends, and Debt Refinancing</a></li>
</ul>



Image via Merck

Analyst Color

Biotech

Earnings

Large Cap

News

Guidance

Health Care

Analyst Ratings

General

Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a lower-than-expected 2025 outlook.

Analysts Defend Merck Amid Investor Concerns Over Weak Guidance

abbvie shutter

AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) will release its full-year and fourth-quarter 2024 financial results on <a href="https://www.benzinga.com/pressreleases/25/01/n42783603/abbvie-to-host-full-year-and-fourth-quarter-2024-earnings-conference-call" target="_blank" rel="noreferrer noopener">Friday, Jan. 31</a>.



Wall Street estimates adjusted EPS of $2.10 and quarterly sales of $14.83 billion, as per data from <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>.



Goldman Sachs sees AbbVie shares as &#8220;attractive at current levels&#8221; but notes that a high-profile catalyst is needed to reignite investor interest after the disappointing results of emraclidine&#8217;s two <a href="https://www.benzinga.com/general/biotech/24/11/41915173/abbvies-schizophrenia-failure-disappoints-but-analysts-show-confidence-in-immunology-portfolio" target="_blank" rel="noreferrer noopener">failed Phase 2 trials</a>.



Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42393882/abbvies-early-parkinsons-candidate-hits-primary-goal-in-pivotal-late-stage-study" rel="noreferrer noopener">AbbVie&#8217;s Early Parkinson&#8217;s Candidate Hits Primary Goal In Pivotal Late-Stage Study</a>



Despite this, the company sees potential in exploring emraclidine as an adjunctive treatment, given its favorable tolerability profile. However, accounting rules required AbbVie to record an impairment charge of about $3.5 billion. 



Wall Street analysts have removed potential revenue from emraclidine in forecasts, viewing any future progress as a bonus—assuming the costs of continuing development are reasonable compared to other investment options.



The company has demonstrated strong execution in its core immunology business, effectively managing Humira&#8217;s loss of exclusivity (LOE) in 2023. Despite a 10% decline in 2023, the franchise is expected to recover, with a 2% overall growth projection for 2024 and stable U.S. performance. 



Growth is forecasted to accelerate to 7% in 2025, with double-digit expansion of 10-11% expected in 2026 and 2027.



Goldman Sachs raised the price forecast from $205 to $208, <a target="_blank" href="https://www.benzinga.com/quote/ABBV/analyst-ratings" rel="noreferrer noopener">with a Buy rating</a>, reflecting confidence in the upside potential from key Immunology growth drivers, Skyrizi/Rinvoq.



Goldman Sachs writes the key updates are focused on the revenue outlook for major immunology products. For 2025 and 2026, analyst Chris Shibutani has increased Skyrizi forecasts by 1.4% and 3.1%, respectively, driven by strong performance and potential in treating inflammatory bowel diseases. 



Rinvoq forecasts also see a slight boost of 0.4% for both years. The analyst is closely watching Phase 3 trial results for additional uses, such as alopecia areata and vitiligo, expected in 2025 to guide long-term growth projections.



Price Action: ABBV stock is up 3.5% at $176.32 at last check Monday.



Read Next:



<ul>
<li><a href="https://www.benzinga.com/25/01/43240220/atlas-energy-to-acquire-moser-energy-in-220-million-sees-q4-fy-revenue-below-consensus" target="_blank" rel="noreferrer noopener">Atlas Energy To Acquire Moser Energy In $220 Million Deal, Sees Q4 &amp; FY Revenue Below Consensus</a></li>
</ul>



Photo: Shutterstock

Movers

Trading Ideas

ABBV

AbbVie plans to release Q4 2024 results on Jan. 31. Analysts predict $14.8 billion in sales, $2.10 EPS. Immunology growth remains a key focus for investors.

AbbVie Builds Momentum With Immunology Growth, Goldman Remains Positive

Johnson&amp;Johnson.Shutterstock

On Wednesday, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) reported a fourth-quarter adjusted EPS of $2.04, down 10.9% year over year, <a href="https://www.benzinga.com/25/01/43125966/johnson-johnson-reports-q4-earnings-above-wall-street-estimates-driven-by-strong-cancer-drugs-revenue">beating the consensus of $2.01</a>.



The pharmaceutical giant reported sales of $22.52 billion, up 5.3% year over year and beating the consensus of $22.44 billion.



Operational growth was 6.7%, and adjusted operational growth was 5.7%.



Raymond James noted that the company&#8217;s initial 2025 EPS guidance was slightly better than anticipated, despite facing foreign exchange (FX) challenges. However, the MedTech segment remains weak, with Johnson &amp; Johnson defending its position in key franchises.



Also Read: <a href="https://www.benzinga.com/general/biotech/25/01/43105398/fda-approves-johnson-johnsons-treatment-as-first-monotherapy-for-treatment-resistant-depression">FDA Approves Johnson &amp; Johnson&#8217;s Treatment As First Monotherapy For Treatment-Resistant Depression</a>



Raymond James analyst Jayson Bedford wrote that increased M&amp;A activity could support long-term growth, but near-term challenges include soft electrophysiology (EP) performance and the impact of Stelara's loss of exclusivity. The analyst maintained an Outperform rating.



BofA Securities viewed Johnson &amp; Johnson as fairly valued, noting its above-average price-to-earnings (P/E) ratio but only average long-term growth prospects based on their analysis.



Potential upside could depend on the outcome of talc litigation expected in the first half of the year, and results from late-stage clinical trials for Johnson &amp; Johnson&#8217;s pipeline drugs.



BofA analyst Tim Anderson slightly reduced the price forecast from $160 to $159 with a Neutral rating.



Stifel noted Johnson &amp; Johnson started the fourth-quarter 2024 MedTech earnings season on a generally positive note. However, the MedTech division faced challenges from increased competition in PFA catheter adoption and China's volume-based procurement (VBP) policies. While these pressures are expected to persist, the division&#8217;s overall outlook remains optimistic.



MedTech growth was anticipated to pick up in the second half of 2025 as the business moves past tougher year-over-year comparisons in the first quarter and benefits from momentum gained by newly launched products throughout the year.



Stifel analyst Rick Wise maintained a Hold rating on Johnson &amp; Johnson shares, and suggested there may be better opportunities to invest based on timing and valuation.



Goldman Sachs analyst Chris Shibutani said the oncology segment, once again headlined by the very strong multiple myeloma franchise, delivered yet again amid high expectations.



The challenges unsurprisingly percolate within immunology, where some turbulence for Tremfya added to the burden of responsibility for the product ahead of key IBD launches.



JNJ Price Action: Johnson &amp; Johnson stock was up 1% at $146.80 at last publication Thursday.



Read Next:



<ul>
<li><a href="https://www.benzinga.com/25/01/43168601/marinemax-q1-earnings-beats-estimates-shares-soar-13-despite-revenue-dip">Yacht Company MarineMax&#8217;s Q1 EPS Surprises, Despite Sales Decline And Hurricane Disruption</a></li>
</ul>



Photo: Shutterstock

Price Target

Analysts discuss Johnson &amp; Johnson&#39;s outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.

Johnson &amp; Johnson&#39;s MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst

Eli-Lilly-and-Company-Zepbound-Vials

Just before the JP Morgan healthcare conference, Eli Lilly and Co&nbsp;(NYSE:&nbsp;LLY) announced that it expects 2024 full-year worldwide revenue to be approximately&nbsp;$45.0 billion, representing a 32% growth compared to the previous year versus the&nbsp;<a target="_blank" href="https://www.benzinga.com/25/01/42976923/eli-lilly-expects-around-55-billion-sales-from-weight-lossdiabetes-drugs-with-overall-topline-growth-of-32-issues-2025-forecast" rel="noreferrer noopener">consensus of $45.50 billion</a>.



The company's expected 2024 revenue is&nbsp;$400 million, or about 3%, below the guidance range issued during the&nbsp;third-quarter earnings. The guidance includes approximately&nbsp;$3.5 billion&nbsp;for Mounjaro and $1.9 billion&nbsp;for Zepbound.



During the conference, David Ricks outlined two reasons for the guidance update:



<ul>
<li>The diabetes GLP market, in December, outperforms the rest of the quarter and in year this did not happen&#8230;The CEO said this could be just a guess. The company said it did not predict it. "This year that didn't happen in GLP-1," said Ricks, who speculated that changes in Medicare Part D and insurance edits have prevented patients from doubling up their prescriptions at the end of the year to avoid deductible costs early in the following year."</li>



<li>Stocking levels were a big discussion during Q3 results. The company dropped about 8 selling days in that quarter alone. The company expected a buildback at the end of the year because every year, a couple of days of buildback happen, and it did not happen this year.</li>
</ul>



Regarding the guidance approach, the CEO noted, "The scale of this business and the way it's been growing, the consumer part of it, along with the stocking dynamics, it's just been a learning [experience] for us," Ricks said. "Our forecasters really nailed the rest of the portfolio. We don't have a problem with forecasting. It's just, this market is quite different."



Goldman analyst Chris Shibutani writes, "We expect this preliminary 4Q results to heighten concerns relating to underlying demand dynamics, which initially emerged at a broader level amongst investors during the 3Q results and guidance update."



Price Action: LLY stock is up 0.59% at $749.28 at the last check on Wednesday.



Read Next:



<ul>
<li><a href="https://www.benzinga.com/media/25/01/43004444/intel-plans-to-spin-off-5-billion-venture-capital-segment-will-remain-anchor-investor" target="_blank" rel="noreferrer noopener">Intel Plans To Spin Off $5 Billion Venture Capital Segment, Will Remain Anchor Investor</a></li>
</ul>



Photo via Eli Lilly and Company

Eli Lilly forecasts $45 billion revenue for 2024, 32% higher than last year. Medicare changes and stocking issues impact the revised guidance.

Eli Lilly Adjusts Outlook, CEO David Ricks Explains Revenue Shortfall

Pfizer_shutterstock2

Pfizer hosted a discussion with sell-side analysts to provide an update on one of the vaccine pipeline items &#8211; a second-generation Clostridioides difficile (C. diff) vaccine effort in Phase 2.



Goldman Sachs analyst Chris Shibutani maintained a Buy rating on Pfizer, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) with a <a target="_blank" href="https://www.benzinga.com/quote/PFE/analyst-ratings" rel="noreferrer noopener">price target of $33</a>.



Shibutani recalled that Pfizer had reported negative results from a Phase 3 study for a first-generation asset in March 2022, where the primary endpoint was unmet.



Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42645821/elon-musks-xai-expands-with-new-chatbot-app" rel="noreferrer noopener">Elon Musk&#8217;s xAI To Expand With New Chatbot App</a>



Still, results did include signals from secondary endpoints that suggested reduced disease severity.



Pfizer has since been exploring updated formulations (reducing the 3-dose regimen to 2 doses), including a version in Phase 2. Immunogenicity data are anticipated in 2025, with potential for advancement into Phase 3 by the end of 2025.



For a potential Phase 3 study, Shibutani noted the objective would be to discern the potential to reduce the severity of a C. diff infection (CDI) instead of aiming to reduce the risk and prevention of disease.



Pfizer estimates ~500k infections annually in the U.S., and no vaccine options currently available. Acknowledging that there is an unmet need The analyst acknowledged that there is an unmet need and said the data thus far suggests a potential basis for a path forward for the program in the context of comments from R&amp;D leadership during the discussion Shibutani hosted with investors.



The emphasis on the forward will be on programs with the most significant potential for economic returns. The analyst expects that investor enthusiasm will likely remain relatively subdued, especially in the context of uncertainties deriving from health policy dynamics relating to vaccines, that are an overhang to sentiment.



Shibutani does not currently include revenue estimates for a C. diff vaccine in his model and looks to monitor data updates and decisions regarding plans for this program to guide his forecasts in the future.



Separately, the analyst flagged Pfizer management&#8217;s mention of the fourth generation 25-valent pneumococcal vaccine (PCV), which management affirms continues to progress in Phase 2.



Shibutani recalled that Pfizer had previously commented that the immunogenicity data from Phase 1 were encouraging, as highlighted by the improved immunogenicity observed for serotype 3.



Pfizer is currently in a Phase 2 proof-of-concept study for its second-generation Clostridioides difficile (C. diff) vaccine, PF-07831694. This vaccine targets C. diff toxins A and B, which cause Clostridioides difficile infection (CDI).&nbsp;&nbsp;



Their goal for the second generation is to build off the 1st generation&#8217;s efficacy and duration by developing a more potent, more durable formulation, allowing for a 2-dose regiment (instead of 3-dose), resulting in higher and faster series completion.



After evaluating adjuvants in formulation for their next-generation candidates, Pfizer noted they can increase the strength or magnitude of the immune response, potentially resulting in lower doses.



Pfizer advanced 1 of the three updated 2nd-generation candidates to Phase 2 based on Phase 1/2 safety and immunogenicity data.



The Phase 2 trial endpoints will evaluate the immunogenicity and safety of the 2-dose regimen. Trial data is expected in 2025, with a potential Phase 3 start in late 2025, pending positive results.



Pfizer in Phase 2 is the furthest along of the C. diff vaccine assets. Idorsia Pharmaceuticals initiated Phase 1 for their competing C. diff asset in July. Vaxxilon and Matrivax Research &amp; Development Corporation both have preclinical assets. GSK Plc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) CDI vaccine completed a Phase 1 trial in 2022 but is no longer listed as a pipeline asset.&nbsp;&nbsp;



Pfizer&nbsp;stock has dropped over 11.5% year-to-date. Investors can gain exposure to the stock through SPDR S&amp;P 500 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>).



Price Action: PFE stock is up 0.82% at $26.58 at the last check on Monday.



Also Read:



<ul>
<li><a href="https://www.benzinga.com/24/12/42644888/biden-administration-targets-chinese-firm-over-taiwan-semiconductor-chip-found-in-huawei-tech" target="_blank" rel="noreferrer noopener">Biden Administration Targets Chinese Firm Over Taiwan Semiconductor Chip Found in Huawei Tech</a></li>
</ul>



Photo via Shutterstock

Reiteration

Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in Phase 2. Data expected in 2025.

Pfizer&#39;s Progress on C. diff Vaccine and Pneumococcal Shot Wins Analyst Conviction

analyst ratings image

BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) has been analyzed by 21 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">11</td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

Analysts have set 12-month price targets for BioNTech, revealing an average target of $139.59, a high estimate of $171.44, and a low estimate of $96.00. This current average reflects an increase of 17.01% from the previous average price target of $119.30. 
<img src="https://www.benzinga.com/files/images/story/2024/1733950831_0.png" alt="price target chart" />

<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of BioNTech among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$170.00</td>
<td>-</td>
</tr>
<tr>
<td>William Maughan</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$171.44</td>
<td>$171.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$122.00</td>
<td>$124.00</td>
</tr>
<tr>
<td>Cory Kasimov</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$125.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>John Newman</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$171.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$150.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>John Newman</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$171.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Chris Shibutani</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$137.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Yaron Werber</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$122.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Yaron Werber</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$122.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$124.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Yifeng Liu</td>
<td>HSBC</td>
<td>Raises</td>
<td>Buy</td>
<td>$136.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$145.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Emmanuel Papadakis</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$131.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Akash Tewari</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$125.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$113.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Akash Tewari</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$96.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>

<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to BioNTech. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of BioNTech compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for BioNTech's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of BioNTech's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BNTX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on BioNTech analyst ratings.</a>
<h2>Delving into BioNTech's Background</h2>
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
<h3>Unraveling the Financial Story of BioNTech</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: BioNTech's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 39.04%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: BioNTech's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 15.91% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): BioNTech's ROE stands out, surpassing industry averages. With an impressive ROE of 1.04%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): BioNTech's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.89%, the company showcases efficient use of assets and strong financial health.
Debt Management: BioNTech's debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BNTX

Critical Insights From BioNTech Analyst Ratings: What You Need To Know

Eli Lilly (LLY)

Eli Lilly &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) shares have nosedived 12.5% month-to-date through Nov. 19, putting the stock on track for its worst monthly performance since February 2009, when <a href="https://www.benzinga.com/quote/LLY/news">it tumbled 20.2%. </a>



The pharmaceutical giant, which ranks 11th by market capitalization in the S&amp;P 500 and holds the top spot among health care stocks, is reeling from a disappointing third-quarter earnings report and lowered guidance.



The sell-off raised doubts about the near-term prospects for Lilly's high-profile drugs Mounjaro and Zepbound, which missed revenue expectations and contributed to a storm of investor uncertainty.



For traders, the burning question now is whether Eli Lilly's pullback represents an opportunity to "buy the dip" in a high-quality, highly profitable company that maintains a position of dominance in the health care market.



<h1 class="wp-block-heading">Chart: LLY Shares On Track For Worst Month In Over 15 Years</h1>



<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="501" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19124450/image-197-1024x501.png" alt="" class="wp-image-655565" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19124450/image-197-1024x501.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19124450/image-197-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19124450/image-197-768x376.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19124450/image-197-1536x752.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19124450/image-197.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>



<h1 class="wp-block-heading">The Catalyst: Weak Third-Quarter Earnings and Downgraded Guidance</h1>



Eli Lilly's third-quarter earnings report, released on Oct. 30, triggered the stock's steep decline in November.



While the company has been riding high on the success of its diabetes and obesity drugs, Mounjaro and Zepbound, both underperformed this quarter, missing revenue expectations by 14% and 26%, respectively.



Alec W. Stranahan, an analyst at Bank of America, said, "The focus this quarter was again on Mounjaro and Zepbound, which missed revenue expectations by a wide margin."



In response to the weak performance, Eli Lilly adjusted its full-year revenue guidance. 



The company lowered the high end of its forecast, projecting $45.4 billion to $46 billion, down from the previous range of $45.4 billion to $46.6 billion.



Lilly management attributed the third-quarter shortfall to temporary "inventory dynamics" rather than a fundamental decline in demand, reassuring investors that this was not indicative of a broader problem with its flagship drugs.



The company also highlighted its ongoing direct-to-consumer (DTC) promotional efforts, which began in the third quarter and are expected to drive sales growth in the fourth quarter and into 2025.



Despite the negative quarter, Bank of America remains bullish on Eli Lilly despite the recent stumble. Stranahan reaffirmed his "Buy" rating on the stock with a 12-month price target of $1,100, implying a 55% upside from current levels.



Instead, Goldman Sachs took a more cautious stance, maintaining a "Neutral" rating on Eli Lilly with a 12-month price target of $890, implying a 24% upside from current levels.



Chris Shibutani, M.D., described the third quarter as a "challenging update" and flagged the $1 billion shortfall in tirzepatide revenues as a significant concern. 



He expressed skepticism about whether the company can achieve its revised fourth quarter and 2025 revenue guidance.



The analyst urges caution ahead, highlighting that Eli Lilly's guidance assumes significant execution on multiple fronts, from inventory management to international expansion. "These factors need to cooperate for LLY to deliver," Shibutani said.



<h1 class="wp-block-heading">How Did Eli Lilly Shares React After Double-Digit Monthly Sell-offs?</h1>



Double-digit monthly selloffs have been a rarity for Eli Lilly, with only four occurrences in the past 15 years where the stock dropped more than 10% in a single month.



Interestingly, past data shows Eli Lilly has historically rebounded strongly following such declines.



Here's how the stock performed one month and three months after these major sell-offs:



<figure class="wp-block-table is-style-stripes"><table><thead><tr><th>Month</th><th>LLY Monthly Loss (%)</th><th>LLY 1-Month Forward (%)</th><th>LLY 3-Month Forward (%)</th></tr></thead><tbody><tr><td>October 2020</td><td>-11.9%</td><td>+11.6%</td><td>+59.5%</td></tr><tr><td>September 2021</td><td>-10.6%</td><td>+10.2%</td><td>+19.8%</td></tr><tr><td>January 2022</td><td>-11.2%</td><td>+14.6%</td><td>+28.4%</td></tr><tr><td>July 2024</td><td>-11.2%</td><td>+24.1%</td><td>+2.3%</td></tr></tbody></table></figure>



While history doesn't guarantee future results, the data suggests that Eli Lilly shares have demonstrated resilience following steep sell-offs, with gains ranging from 10.2% to 24.1% one month later and a solid average of positive returns over three months.



Read Now:



<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/42041147/novo-nordisk-to-offer-wegovy-in-china-at-fraction-of-usa-cost">Novo Nordisk To Offer Wegovy In China At Fraction Of USA Cost</a></li>
</ul>



Photo: Shutterstock

Equities

Eli Lilly &amp; Co. shares plunge 12.5% this month, worst since 2009, due to disappointing earnings and lowered guidance. The future remains uncertain.

Eli Lilly Stock Eyes Worst Month Since February 2009: Is It Time To Buy The Dip?

Analysts' ratings for BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) over the last quarter vary from bullish to bearish, as provided by 17 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">10</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

Analysts have set 12-month price targets for BioNTech, revealing an average target of $132.24, a high estimate of $171.00, and a low estimate of $96.00. Marking an increase of 19.2%, the current average surpasses the previous average price target of $110.94. 
<img src="https://www.benzinga.com/files/images/story/2024/1731614463_0.png" alt="price target chart" />

<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of BioNTech among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Newman</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$171.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Chris Shibutani</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$137.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Yaron Werber</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$122.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Yaron Werber</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$122.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$124.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Yifeng Liu</td>
<td>HSBC</td>
<td>Raises</td>
<td>Buy</td>
<td>$136.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$145.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Emmanuel Papadakis</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$131.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Akash Tewari</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$125.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$113.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Akash Tewari</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$96.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$113.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$113.00</td>
<td>$113.00</td>
</tr>
</tbody>
</table>

<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to BioNTech. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of BioNTech compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of BioNTech's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BNTX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on BioNTech analyst ratings.</a>
<h2>Delving into BioNTech's Background</h2>
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
<h3>A Deep Dive into BioNTech's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, BioNTech showcased positive performance, achieving a revenue growth rate of 39.04% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: BioNTech's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 15.91%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): BioNTech's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.04% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): BioNTech's ROA excels beyond industry benchmarks, reaching 0.89%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.01, BioNTech adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Landscape: 17 Takes On BioNTech

Analysts' ratings for BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) over the last quarter vary from bullish to bearish, as provided by 17 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, a high estimate of $150.00, and a low estimate of $91.00. This upward trend is apparent, with the current average reflecting a 19.85% increase from the previous average price target of $106.41.
<img src="https://www.benzinga.com/files/images/story/2024/1731092443_0.png" alt="price target chart" />

<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of BioNTech by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Shibutani</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$137.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Yaron Werber</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$122.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Yaron Werber</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$122.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$124.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Yifeng Liu</td>
<td>HSBC</td>
<td>Raises</td>
<td>Buy</td>
<td>$136.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$145.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Emmanuel Papadakis</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$131.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Akash Tewari</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$125.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$113.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Akash Tewari</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$96.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$113.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$113.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$91.00</td>
<td>$94.00</td>
</tr>
</tbody>
</table>

<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to BioNTech. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of BioNTech compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for BioNTech's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of BioNTech's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BNTX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on BioNTech analyst ratings.</a>
<h2>Discovering BioNTech: A Closer Look</h2>
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
<h3>BioNTech's Economic Impact: An Analysis</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining BioNTech's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 39.04% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: BioNTech's net margin excels beyond industry benchmarks, reaching 15.91%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): BioNTech's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.04% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): BioNTech's ROA stands out, surpassing industry averages. With an impressive ROA of 0.89%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About BioNTech Stock

Bank,Of,America,In,Beverly,Hills

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.



<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/595e9280988ca80001bd91e0/arvind-ramnani">Piper Sandler analyst Arvind Ramnani </a>upgraded the rating for Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) from Neutral to Overweight and raised the price target from $31 to $85. Upstart shares closed at $55.47 on Thursday. <a href="https://www.benzinga.com/quote/UPST/analyst-ratings">See how other analysts view this stock</a>.</li>



<li>Goldman Sachs analyst Chris Shibutani upgraded BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) from Neutral to Buy and raised the price target from $90 to $137. BioNTech shares closed at $107.88 on Thursday. <a href="https://www.benzinga.com/quote/BNTX/analyst-ratings">See how other analysts view this stock</a>.</li>



<li>Daiwa Capital analyst Jonathan Kees upgraded the rating for AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) from Neutral to Outperform and raised the price target from $80 to $280. AppLovin shares closed at $246.53 on Thursday. <a href="https://www.benzinga.com/quote/APP/analyst-ratings">See how other analysts view this stock</a>.</li>



<li>Citigroup analyst Keith Horowitz upgraded Bank of America Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) from Neutral to Buy and increased the price target from $46 to $54. Bank of America shares closed at $44.77 on Thursday. <a href="https://www.benzinga.com/quote/BAC/analyst-ratings">See how other analysts view this stock</a>.</li>



<li>Telsey Advisory Group analyst Joseph Feldman upgraded the rating for The Home Depot, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) from Market Perform to Outperform and boosted the price target from $360 to $455. Home Depot shares closed at $399.44 on Thursday. <a href="https://www.benzinga.com/quote/HD/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>



Considering buying BAC stock? Here&#8217;s what analysts think: 



<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="534" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08075932/image-91-1024x534.png" alt="" class="wp-image-637546" style="width:635px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08075932/image-91-1024x534.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08075932/image-91-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08075932/image-91-768x400.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08075932/image-91.png 1276w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>



Read More:<a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win"> </a>



<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>

Upgrades

Pre-Market Outlook

Markets

UPST

This Bank of America Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Analyst Ratings Newsletter

Don't Miss Your Daily Analyst Rating Email!!!

acf/beehiiv-email-capture

acf/raptive-ad-placement